<DOC>
	<DOCNO>NCT00820118</DOCNO>
	<brief_summary>The primary objective trial ass ability early intermittent antiretroviral therapy maintain immunological stability antiretroviral naive HIV infect adult , offer potential alternative strategy differ continuous antiretroviral treatment.This 2-year phase II , open-label , multicentric `` proof concept '' trial . The patient include treated follow pulse-therapy scheme , i.e . 6-month period daily boosted-PI base therapy alternance 6-month period without antiretroviral therapy . The preferentially recommended treatment study atazanavir boost ritonavir , associate fix combination abacavir lamivudine emtricitabine + tenofovir.The patient closely follow assess efficacy tolerance strategy , clinical , biochemical , immunological , virological pharmacokinetic evaluation .</brief_summary>
	<brief_title>Early Intermittent Antiretroviral Therapy Naive HIV Infected Adults</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>adult confirm HIV1 infection previous treatment antiretroviral drug interleukin2 CD4 count â‰¥ 500/mm3 active opportunistic infection write informed consent non barrier contraception woman child bear potential , pregnant breastfeed woman , pregnancy project within next 2 year HIV2 infection ( without HIV1 ) , recent HIV primary infection , resistance trial drug study entry , Ag HBs+ , HCV require specific therapy previous history cerebrovascular accident coronary heart disease , splenectomy previous CD4 count &lt; 400/mm3 CD4 percentage &lt; 15 % hemoglobin &lt; 8 g/dl , neutrophils &lt; 750/mm3 , platelet &lt; 100.000/mm3 , creatinine clearance &lt; 50 ml/mn , AST ALT total bilirubin &gt; 3 ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>ANTIRETROVIRAL THERAPY</keyword>
	<keyword>STRUCTURED TREATMENT INTERRUPTIONS</keyword>
	<keyword>treatment naive</keyword>
</DOC>